NCT06640088 (DISCOVER) is a clinical trial in Brain Death, sponsored by University Hospital, Basel, Switzerland.

Who is sponsoring NCT06640088?

NCT06640088 is sponsored by University Hospital, Basel, Switzerland.

What condition does NCT06640088 study?

NCT06640088 studies Brain Death.

Is NCT06640088 still recruiting?

NCT06640088 is currently recruiting now. Last updated 16 October 2024.

Last reviewed 2024-10-16 · How we verify

NCT06640088: DISCOVER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Determining ICU Staffs Conceptions, Opinions, Views, Experiences and Reflection of Brain Death and Organ Donation

Recruiting now Last updated 16 October 2024

What this trial tests

trial in Brain Death in 200 participants. Currently enrolling.

Timeline

14 October 2024

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	University Hospital, Basel, Switzerland
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	200
Start date	14 October 2024
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	1 location across Switzerland

Conditions studied

Brain Death — all drugs for Brain Death →

Sponsor

University Hospital, Basel, Switzerland

Who can join

18 and older, any sex, with Brain Death. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to gather information regarding the individual perceptions, opinions, beliefs, and conceptual understanding of healthcare professionals working in the intensive care units at the University Hospital Basel and to determine associations of individual beliefs, personal, educational, and professional experiences with individual perceptions, opinions, and conceptual understanding regarding brain death and organ donation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University Hospital, Basel, Switzerland trials

Trials by the same sponsor.

NCT07444788 — Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants · Phase 1 · recruiting
NCT07494214 — Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants · Phase 1 · recruiting
NCT07419048 — Artificial Intelligence or Human Hand? Evaluating Inferior Vena Cava Imaging for Hydration Status · recruiting
NCT06978777 — Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity · NA · recruiting
NCT07273630 — Effect of Protein Supplementation and Fluid Restriction on Plasma Sodium Levels in Patients Undergoing Pituitary Surgery · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06640088 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Basel, Switzerland
Last refreshed: 16 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06640088.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing